全文获取类型
收费全文 | 2876篇 |
免费 | 194篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 54篇 |
妇产科学 | 86篇 |
基础医学 | 407篇 |
口腔科学 | 22篇 |
临床医学 | 273篇 |
内科学 | 689篇 |
皮肤病学 | 124篇 |
神经病学 | 466篇 |
特种医学 | 52篇 |
外科学 | 257篇 |
综合类 | 5篇 |
一般理论 | 1篇 |
预防医学 | 181篇 |
眼科学 | 33篇 |
药学 | 201篇 |
中国医学 | 7篇 |
肿瘤学 | 216篇 |
出版年
2024年 | 7篇 |
2023年 | 41篇 |
2022年 | 101篇 |
2021年 | 150篇 |
2020年 | 87篇 |
2019年 | 96篇 |
2018年 | 110篇 |
2017年 | 93篇 |
2016年 | 108篇 |
2015年 | 133篇 |
2014年 | 154篇 |
2013年 | 195篇 |
2012年 | 263篇 |
2011年 | 245篇 |
2010年 | 115篇 |
2009年 | 119篇 |
2008年 | 183篇 |
2007年 | 176篇 |
2006年 | 149篇 |
2005年 | 143篇 |
2004年 | 113篇 |
2003年 | 99篇 |
2002年 | 91篇 |
2001年 | 18篇 |
2000年 | 12篇 |
1999年 | 12篇 |
1998年 | 13篇 |
1997年 | 14篇 |
1996年 | 5篇 |
1995年 | 8篇 |
1994年 | 9篇 |
1993年 | 6篇 |
1992年 | 3篇 |
1990年 | 1篇 |
1989年 | 3篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1962年 | 1篇 |
1956年 | 1篇 |
排序方式: 共有3095条查询结果,搜索用时 15 毫秒
71.
72.
73.
Leonardo Calza Elisa Vanino Eleonora Magistrelli Caterina Salvadori Alessandra Cascavilla Vincenzo Colangeli Maria Assunta Di Bari Roberto Manfredi Pierluigi Viale 《Clinical and experimental nephrology》2014,18(1):104-112
Background
Renal disease is an increasingly recognized noninfectious comorbidity associated with human immunodeficiency virus (HIV) infection.Methods
Our retrospective, cross-sectional study evaluated prevalence of nephropathy among HIV-infected patients followed up in our outpatient clinic during the year 2011. Renal dysfunction and chronic kidney disease (CKD) were defined as estimated glomerular filtration rate (eGFR) <90 ml/min per 1.73 m2 and as renal damage or eGFR <60 ml/min per 1.73 m2 over a 3-month or greater period, respectively.Results
We enrolled 894 HIV-infected patients with a mean age of 44.2 years and a mean current CD4 lymphocyte count of 508 cells/mm3. The prevalence of renal dysfunction and CKD was 27.4 and 21.3 %, respectively. Older age, male gender, hypertension, diabetes, proteinuria, hypertriglyceridemia, lower nadir CD4 cell count, current use of tenofovir or tenofovir plus a ritonavir-boosted protease inhibitor were independently associated with renal dysfunction.Conclusion
Renal dysfunction is a frequent comorbidity among HIV-infected persons and requires a careful clinical and laboratory monitoring of renal function. 相似文献74.
75.
Annamaria Aloisio Nancy Nistic Selena Mimmi Domenico Maisano Eleonora Vecchio Giuseppe Fiume Enrico Iaccino Ileana Quinto 《Viruses》2021,13(4)
Receptor tyrosine kinases (RTKs) regulate critical physiological processes, such as cell growth, survival, motility, and metabolism. Abnormal activation of RTKs and relative downstream signaling is implicated in cancer pathogenesis. Phage display allows the rapid selection of peptide ligands of membrane receptors. These peptides can target in vitro and in vivo tumor cells and represent a novel therapeutic approach for cancer therapy. Further, they are more convenient compared to antibodies, being less expensive and non-immunogenic. In this review, we describe the state-of-the-art of phage display for development of peptide ligands of tyrosine kinase membrane receptors and discuss their potential applications for tumor-targeted therapy. 相似文献
76.
Andrea Casadei-Gardini Giulia Rovesti Vincenzo Dadduzio Caterina Vivaldi Eleonora Lai Sara Lonardi Lorenzo Fornaro Andrea Pretta Vittorina Zagonel Laura Bernardini Giorgio Astara Francesco E. D'Amico Gianluca Masi Margherita Rimini Mario Scartozzi Stefano Cascinu 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2021,23(6):915-920
Background and aimThe aim of our retrospective study is to evaluate the prognostic significance of aspirin in patients with advanced HCC treated with sorafenib.Methods304 patients with HCC,consecutively treated with sorafenib from May 2007 to September 2018, were included in the clinical study. Of Them 93 patients token aspirin. Progression-free survival (PFS)and overall survival (OS)were estimated with the Kaplan–Meier method and compared with the log-rank test.ResultsThe concomitant use of sorafenib and aspirin was associated with a median OS of 18.3 months compared to 8.8 months of patients who did not receive aspirin (HR 0.57; P < 0.0001). The concomitant use of sorafenib and aspirin was associated with a median PFS of 7.3 months compared to 3.0 months of patients who did not receive aspirin (HR 0.61; P = 0.0003). In the multivariate analysis, the use of aspirin maintained an independent prognostic value for OS(HR 0.61; P = 0.0013). In second line the concomitant use of regorafenib and aspirin was associated with a median OS of 16.9 months compared to 8.0 months of patients who did not receive aspirin (HR 0.30; P = 0.02).ConclusionGlobally, our data seem to suggest that aspirin use may improve the clinical outcome of patients with advanced hepatocellular carcinoma receiving sorafenib and regorafenib. 相似文献
77.
Fernando Rizzello Carlo Calabrese Marco Salice Lucia Calandrini Hana Privitera Laura Melotti Giulia Peruzzi Nikolas Dussias Andrea Belluzzi Eleonora Scaioli Anastasio Decorato Antonio Siniscalchi Eleonora Filippone Silvio Laureti Matteo Rottoli Gilberto Poggioli Paolo Gionchetti 《Digestive and liver disease》2021,53(3):271-276
BackgroundItaly has been one of the most affected countries in the world by COVID-19. There has been increasing concern regarding the impact of COVID‐19 on patients with inflammatory bowel disease (IBD), particularly in patients treated with immunosuppressants or biologics. The aim of our study is to understand the incidence of COVID-19 in a large cohort of patients with IBD. Furthermore, we analyzed possible risk factors for infection and severity of COVID-19.MethodsThis was an observational study evaluating the impact of COVID-19 on IBD patients in a single tertiary center. A 23 multiple-choice-question anonymous survey was administered to 1200 patients with IBD between March 10th and June 10th 2020.Results1158 questionnaires were analyzed. The majority of patients had Crohn's disease (CD) (60%) and most of them were in clinical remission. Among the 26 patients (2.2%) who tested positive for COVID-19, only 5 (3CD) were on biological treatment and none required hospitalization. Two patients died and were on treatment with mesalazine only. Of the 1158 patients, 521 were on biological therapy, which was discontinued in 85 (16.3%) and delayed in 195 patients (37.4%). A worsening of IBD symptoms was observed in 200 patients on biological therapy (38.4%). Most of these patients, 189 (94.5%), had stopped or delayed biological treatment, while 11 (5.5%) had continued their therapy regularly (p<0.001).ConclusionsOur data are in line with the current literature and confirm a higher incidence compared to the general population. Biological therapy for IBD seems to not be a risk factor for infection and should not be discontinued in order to avoid IBD relapse. 相似文献
78.
Giuseppe Attanasio Edoardo Covelli Laura Cagnoni Eleonora Masci Davide Rosati Edoardo Di Porto 《Acta oto-laryngologica》2015,135(10):969-973
Conclusions: The present study shows that AGE, DELAY, and PTA_PRE may be considered factors influencing therapeutic success in intra-tympanic steroid therapy. Objective: The aim of the study is to evaluate the relationship between the therapeutic success of intra-tympanic prednisolone therapy and age, in patients affected by idiopathic sudden sensorineural hearing loss (ISSNHL), considering the influence of factors such as delay, gender, and pure tone average (PTA) pre-therapy. Method: This retrospective study involved 402 consecutive patients, affected by unilateral ISSNHL between January 2009 and January 2014. Patients were divided into two groups based on age: group one with 94 patients aged over 65 years and group two with all 402 patients enrolled in the study, including those over 65. Results: PTA recorded before the beginning of the therapy (PTA_PRE) in group one was worse than for group two. In both groups the therapy was significantly effective in improving hearing thresholds, even if PTA_PRE was significant and negatively correlated with success rate. This effect disappeared within the population over 65. On average, each day of DELAY from the onset of hearing loss to the beginning of therapy cuts almost 2% of the possibility to recover. AGE was negative and significant when specified continuously for group two. 相似文献
79.
80.
Julie Y. Son Benjamin Chandler Eleonora Feketova Yung Qin Elizabeth J. Quackenbush Edwin A. Deitch 《The Journal of surgical research》2014